Purpose The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted treatment strategies. We assessed whether MRD-positive and MRD-negative patients with AML benefit differently from the graft-versusleukemia effect of allogeneic hematopoietic stem-cell transplantation (alloHSCT).
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by a variety of underlying cytogenetic and molecular aberrations, which are associated with distinct prognostic features. 1 Although current treatment approaches induce high percentages of hematologic remission, relapse rates are high and vary according to the underlying risk profile. 2 Recently, the European LeukemiaNet (ELN) developed an updated classification on the basis of cytogenetic and molecular aberrancies distinguishing patients with a favorable, intermediate, or adverse treatment response. 3 Postremission treatment (PRT) decisions are currently tailored according to AML risk groups, whereby allogeneic hematopoietic stem-cell transplantation (alloHSCT) is generally not used in patients with favorable-risk AML, but is generally highly recommended in patients with adverse-risk AML. [3] [4] [5] [6] AML risk classification may be further improved by introducing the assessment of minimal residual disease (MRD) early after induction chemotherapy, but also after PRT. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Assessment of MRD after induction treatment for specific markers by either multiparametric flow cytometry or quantitative polymerase chain reaction has firmly been shown to predict relapse and overall outcome, regardless of the type of PRT. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Consequently, MRD negativity was introduced as a clinical end point in patients with a hematologic complete remission (CR). 3 Despite PRT with alloHSCT, a twoto five-fold increased incidence of relapse in MRD-positive patients was observed compared with MRD-negative patients, [17] [18] [19] [20] [21] [22] [23] [24] which raises the question of whether and to what extent MRD-positive patients may benefit from the graft-versus-leukemia (GVL) effect of alloHSCT. Conversely, the low relapse rate in MRD-negative alloHSCT recipients also evokes the question of whether GVL is operational in that subgroup and to what extent it may be blunted by nonrelapse mortality (NRM). Therefore, we evaluated whether and to what extent alloHSCT quantitatively reduces relapse compared with conventional PRT in upfront-treated patients with MRD-positive or MRD-negative AML in first CR (CR1).
METHODS

Patients
Patients participated in three prospective, consecutive Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative group trials (AML42, AML92, and AML102; the Netherlands Trial Register numbers NTR230, NTR1446, and NRT2187, respectively), for whom assessment of MRD after induction therapy and before PRT by alloHSCT, chemotherapy, or autologous HSCT (autoHSCT) was performed. 25, 26 The results of the AML92 trial have not yet been published, but trial information is available in the Netherlands Trial Register (NTR1446). A total of 1,511 newly diagnosed patients with AML were included for whom treatment was started between 2006 and 2014. Patients were excluded if CR1 did not occur after two induction cycles of chemotherapy (n = 255; 17%) or the patient did not receive PRT after obtaining CR1 (n = 234; 15%). In addition, a total of 475 patients (31%) received PRT in CR1; however, their MRD status was not available within a time window of 4 months before PRT. A total of 547 patients with available MRD status who received PRT in CR1 were available for analysis ( Fig 1) . Patients were classified by AML prognostic risk on the basis of the cytogenetic and molecular profile of the underlying AML, according to the ELN2017 risk classification. 3 Molecular analysis was available for the majority of patients, specifically for NPM1 (93%); fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD; 91%), including the FLT3-ITD mutant to wild-type ratio (86%); EVI1 (79%); ASXL1 (83%); RUNX1 (47%); and TP53 (47%). Patients for whom molecular analyses were not available were considered as not having the mutation in calculating the ELN2017 risk classification. All studies were approved by the ethics committees of participating institutions and were conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent. A detailed description of the inclusion and exclusion criteria of the studies can be found in the Data Supplement.
Treatment Protocols
Treatment in the HOVON-SAKK AML42A, AML92, and AML102 trials involved a maximum of two remission induction cycles consisting of a first course of idarubicin with cytarabine and a second cycle of high-dose cytarabine with amsacrine, as previously described. 25, 26 Patients were randomly assigned to granulocyte-colony stimulating factor (AML42A), laromustine (AML92), and clofarabine (AML102). After obtaining CR1, patients subsequently received PRT to a predefined strategy as outlined in the study protocols, but without knowledge of the patients' MRD status. PRT included a third cycle of chemotherapy with mitoxantrone and etoposide, high-dose chemotherapy with busulfan and cyclophosphamide followed by autoHSCT, or alloHSCT after either myeloablative conditioning or reduced intensity conditioning (RIC). The myeloablative conditioning regimen contained high-dose cyclophosphamide with at least 8 Gy total body irradiation (TBI) in 83 patients (76%); the remainder of the patients received busulfan with cyclophosphamide. Although RIC regimens varied, the majority contained low-dose (2 or 4 Gy) TBI preceded by fludarabine (n = 126; 77%), whereas 23% of the patients received fludarabine with busulfan. These different PRT modalities were applied according to a riskadapted strategy: patients with AML classified as favorable risk, according to cytogenetic and molecular analysis, were planned for a third cycle of chemotherapy; intermediate-risk patients were preferentially treated with alloHSCT using an HLA-matched sibling donor or a fully HLAmatched unrelated donor, if available; patients with adverse-risk AML proceeded to alloHSCT using a sibling donor, an unrelated donor, or cord blood grafts; and patients alternatively received autoHSCT or a third cycle of chemotherapy if no suitable donor was available. [25] [26] [27] [28] 
MRD Detection and Sample Selection
MRD flow cytometric analysis was performed in a two-step procedure, as previously described. 18 In summary, the immunophenotype was determined on blasts defined by CD45 expression with a low sideward scatter. The leukemia-associated immunophenotype (LAIP) at diagnosis was identified by detecting aberrantly expressed markers/marker combinations to distinguish leukemic blasts from normal hematopoietic progenitor cells. Bone marrow samples were collected at diagnosis to determine LAIP and follow-up after each chemotherapy cycle. The sensitivity of flow cytometry could lead to detection of one leukemic cell in 1,000, up to 100,000 WBCs. MRD percentage was defined as the percentage of LAIP cells within the WBC compartment multiplied by the correction factor (100% divided by the percentage of LAIPpositive blasts at diagnosis). A percentage above 0.1% was considered MRD-positive, as validated in previous studies. 18 MRD samples obtained after cycle 2 in patients with AML in CR1 were used, with a maximum time from the MRD sample to subsequent PRT of 4 months. The sample with the shortest time interval between PRT and the date of collection was selected for analysis.
End Points
The primary end point of the study was the cumulative incidence of relapse. Outcome estimates were measured from the date of starting the first PRT. Overall survival (OS) was based on death from any cause; patients were censored at the date of last contact, if alive. The events for relapse-free survival (RFS) were death in CR1, designated as NRM, or hematologic relapse. The cumulative risks of relapse and NRM over time were calculated as competing risks with actuarial methods, where patients alive in continuing CR1 were censored at the date of last contact.
Statistical Methods
A time-dependent analysis of PRT was performed as described previously 28, 29 by applying multivariable Cox regression with alloHSCT as the timedependent covariable. The multivariable analysis is conceptually similar to a Mantel-Byar analysis, 30 but is more general because it allows for adjustment of other factors. A number of patients received PRT with chemotherapy (n = 44) first before they proceeded to alloHSCT in continuing CR1. In both the multivariable analysis and the estimation of the survival curves, these patients were counted as at risk in the chemotherapy group from the start of PRT until alloHSCT and after that as at risk in the alloHSCT group. Forward selection with the variables significantly associated with relapse after univariable analysis was used for developing the multivariable model. Multivariable Cox regression analysis for relapse, OS, RFS, and NRM was applied, stratified by the total number of induction courses. Stratification by the total number of induction courses (ie, I or II) was performed to allow the baseline hazard to differ between these two patient groups. All P values were based on log likelihood ratio tests, except when explicitly stated otherwise. The proportional hazard assumption was tested on the basis of Schoenfeld residuals. 30 
RESULTS
Patient Characteristics
A total of 547 patients with AML in CR1 and available MRD status proceeded to PRT with either alloHSCT (n = 282), chemotherapy (n = 160), or autoHSCT (n = 105). A total of 129 patients (24%) were MRD positive after induction chemotherapy before proceeding to first PRT. Patient characteristics are listed in Table 1 . Patients with mutated NPM1 were more frequently MRD negative, whereas MRD-positive patients more frequently tended to obtain a late CR1 (ie, after induction cycle 2). The ELN2017 risk classification was similarly distributed among the MRD-negative and MRD-positive patients. Interestingly, the time interval from CR1 to PRT for patients with MRD-positive AML was shorter compared with their negative counterparts, which was mainly apparent in favorablerisk patients with AML. The median follow-up of patients still alive was 50 months. Details of the characteristics of alloHSCT are listed in incidence of relapse in MRD-negative patients compared with MRD-positive patients (32% 6 2% compared with 54% 6 4% at 4 years; P , .001, respectively; Fig 2C) , whereas NRM was not significantly different and estimated at 10 6 1% ( Fig 2D) . More detailed outcome estimates according to MRD status, type of PRT, and risk of NRM on the basis of the EBMT risk score are presented in the Data Supplement.
The cumulative incidence of relapse was significantly lower in patients without MRD receiving alloHSCT compared with chemotherapy or autoHSCT (26% 6 3% v 38% 6 3% at 4 years; P = .027, respectively; Fig 3A) . The cumulative incidence of relapse in MRD-positive patients is estimated to be 45% 6 6% compared with 66% 6 6% at 4 years (P = .058) for recipients of alloHSCT compared with recipients of chemotherapy or autoHSCT, respectively ( Fig 3B) . RFS after alloHSCT proved similar compared with PRT with chemotherapy or autoHSCT in patients without MRD before PRT (58% 6 4% v 58% 6 4% at 4 years; P = .99, respectively; Fig 3C) . RFS after alloHSCT in MRD-positive patients before PRT was 44% 6 6% compared with 31% 6 6% at 4 years (P = .20) after chemotherapy or autoHSCT, respectively ( Fig 3D) . The type of conditioning did not significantly affect the incidence of relapse or RFS (Data Supplement). The cumulative incidence of NRM after alloHSCT was 15% 6 2% and was significantly affected by the EBMT risk score (Data Supplement). NRM split by the EBMT risk score showed less NRM in patients with a low EBMT risk score compared with patients with a high EBMT risk score (< 2 compared with . 2); 10% 6 2% compared with 22% 6 4%; P = .005, respectively.
A total of 208 patients developed a relapse after having received PRT, of whom 120 (57%) proceeded to salvage chemotherapy and 70 (59%) entered a second CR. Only 46 of relapsing patients (22%) proceeded to alloHSCT after obtaining a second CR.
Multivariable Analysis
The following variables significantly predicted for relapse in the univariable analysis: MRD status, type of PRT, age, WBC category, FLT3-ITD category, year of PRT, time from diagnosis to CR, time from CR to PRT, cytogenetics, number of cycles to CR, ELN2017 risk classification, NPM1 mutation, EVI1 overexpression, and CEBPA double mutation. After forward selection, the multivariable analysis was performed, stratified by the total number of induction courses with adjustment for MRD status, type of PRT, age, WBC category at diagnosis, FLT3-ITD, ELN2017 risk classification, number of cycles to CR, and year of PRT ( Table 3 ). Relapse of AML was significantly reduced after alloHSCT compared with chemotherapy or autoHSCT (HR, 0.36; P , .001). This hazard ratio quantifies the allogeneic GVL-effect of alloHSCT. That GVLeffect was similarly exerted in MRD-negative and MRD-positive patients (HR, 0.38; P , .001; and HR, 0.35; P , .001; Fig 4A) , which was also similar comparing alloHSCT with chemotherapy or alloHSCT with autoHSCT (Data Supplement). Despite significantly increased NRM (HR, 2.94; P = .003), RFS was better after alloHSCT compared with chemotherapy or autoHSCT (HR, 0.53; P , .001, Fig 4B; Data Supplement), whereas OS was not significantly different (Table 3) . Different variables in the multivariable model were significantly associated with relapse, with the ELN2017 risk classification, FLT3-ITD mutant to wild-type ratio, number of cycles to reach CR, and type of PRT being the most important variables.
DISCUSSION
The development of treatment approaches in patients with AML is increasingly personalized by using genetic and molecular leukemia characteristics at diagnosis and individual treatment response. [3] [4] [5] [6] Response and especially MRD, detected by either multiparametric flow cytometry or quantitative polymerase chain reaction, has become an important parameter in a more precise treatment approach for patients with AML. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Currently, it is unknown whether and how the presence or absence of MRD should guide the application of alloHSCT as PRT. Recently, the quantitative detection of mutated NPM1 has been shown to have high predictive value, and recommendations to tailor the application of alloHSCT by MRD were made. [10] [11] [12] Balsat et al 10 suggested refraining from alloHSCT in NPM1 MRDnegative patients and to selectively proceed to alloHSCT as PRT in CR1 in MRD-positive patients or adverse-risk patients on the basis of karyotype or the presence of FLT3-ITD. In addition, Buccisano et al 33 concluded in a recent analysis that MRD-positive patients, as determined by flow cytometry, could also benefit from alloHSCT. Although it has been suggested that overall outcome is improved by alloHSCT in MRD-positive patients, it is still unknown to what quantitative extent alloHSCT reduces relapse in MRD-positive patients and how that compares with MRD-negative patients.
Here, we show that the allogeneic GVL effect-as estimated by the relative reduction of relapseis similar in MRD-positive and MRD-negative patients, with a reduction of 63% by alloHSCT compared with chemotherapy or autoHSCT. These results compare well with earlier findings in cytogenetic subgroups, in which the GVL effect seemed to be similar among patients with a monosomal karyotype, core binding factor AML, or normal karyotype. 34 These observations are most readily explained by the abundant expression of class I and II HLA antigens on malignant myeloid precursor cells and their susceptibility to alloreactive T cells, including T cells recognizing minor or major HLA antigens. [35] [36] [37] They suggest that T-cell alloreactivity might exert antileukemic effects regardless of the underlying subcategory of AML, although absolute estimates of relapse incidence do differ and may rather reflect differences in disease biology, such as intrinsic resistance.
Although alloHSCT provides a strong GVL effect, counterbalancing NRM may be of concern. Because NRM critically depends on a number of different risk factors, it has become imperative to assess the NRM risk profile in addition to leukemia characteristics and response to induction chemotherapy. 4 In the current study, the subset of patients with low EBMT risk scores showed an excellent outcome, whereas the GVL effect of alloHSCT may be blunted by NRM in patients with a high risk of NRM. Therefore, refined leukemia risk scores that predict for relapse should be weighed together with the latest risk scores for NRM. 32, [38] [39] [40] [41] [42] [43] [44] Transplantation risk scores have been developed and validated based on patient and transplantation characteristics, including the EBMT risk score 32 and the Hematopoietic Cell Transplantation-Comorbidity Index, 40 which is continuously being refined, including age, disease status, or biomarkers. 39, 41, 42 The EBMT Acute Leukemia Working Party has developed an integrated score on the basis of the EBMT-risk score and the Hematopoietic Cell Transplantation-Comorbidity Index with increased predictive power in the setting of RIC alloHSCT. 43 Alternatively, a more sophisticated, machinebased learning model was developed by the EBMT-Acute Leukemia Working Party, which resulted in an alternating decision tree model with high predictive power for mortality at 100 days, extending to 2 years. 44 As advocated before, by weighing both the risk of NRM and the risk of relapse, a more personalized treatment approach can be applied. 5 Although that approach suits the precision needed for individual patients, it might also impair the prospective, randomized evaluation of AML treatment approaches, because patient selection may occur at various time points during treatment. Nevertheless, the advantages of personalized treatment are obvious and continuously being refined by updated and better methods of risk assessment. Also, new technologies to better define MRD, such as quantification of leukemic stem-cell content, standardized protocols and antibody panels, and novel software possibilities, are emerging. [45] [46] [47] A personalized approach including MRD identifies patients with a high risk of relapse who qualify for alloHSCT, but who might benefit from attempts to induce MRD negativity before transplantation. Previously, a number of investigators reported that patients in CR1 with persistence of MRD before alloHSCT have worse survival compared with recipients of alloHSCT with an MRD-negative CR1. 17, [19] [20] [21] [22] [23] [24] Although alloHSCT is clearly indicated in MRD-positive patients, it is important to study the value of approaches intended to induce MRD negativity before alloHSCT. A prospective inclusion of all MRD-positive patients and subsequently analyzing such a strategy in a randomized fashion might answer this important question. It has been suggested that continued chemotherapy with one or two consolidation cycles may not be the preferred strategy to obtain an MRD-negative CR before alloHSCT, 48 but several new drugs are currently being developed and evaluated for AML. 49 Possible other strategies may include efforts to improve allogeneic immunotherapy by early tapering of immunosuppression and/or preemptive donor lymphocyte infusions, which also could be guided by MRD. In addition, the continued application of novel post-transplantation strategies, including epigenetic therapy to enhance the GVL effect (ie, demethylating agents and histone deacetylase inhibitors 50, 51 ) , new agents, such as tyrosine kinase inhibitors for specific molecular mutations (ie, FLT3-ITD, 52 IDH1/2 53, 54 ), or targeted immunotherapy with chimeric antigen receptor T cells in MRD-positive patients, may offer more therapeutic options to minimize relapse after alloHSCT. Abbreviations: allo, allogeneic hematopoietic stem-cell transplantation; auto, autologous hematopoietic stem-cell transplantation; CR, complete remission; CT, chemotherapy; ELN2017, European LeukemiaNet 2017; FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; HR, hazard ratio; MRD, minimal residual disease; NRM, nonrelapse mortality (with event death in first CR and censored at relapse); OS, overall survival (with event death whatever the cause); PRT, postremission treatment; relapse, with time as RFS and with event relapse and censored at death in first CR; RFS, relapse-free survival (with event death in first CR or relapse). *The HRs are the estimates of the effect of covariables for each outcome parameter, stratified by the number of induction courses and adjusted for type of PRT, MRD status, age, WBC count at diagnosis, FLT3-ITD category, ELN2017-risk, number of cycles to CR, and year of PRT. †Linear with estimates of 10 years difference.
Collectively, our study shows that the GVL effect was strikingly similar in MRD-positive and MRDnegative patients. The personalized application of alloHSCT should take MRD response into account, in addition to risk scores for NRM, because GVL is not invariably blunted by NRM. Additional prospective studies are needed to evaluate whether the conversion of MRD positivity into an MRD-negative remission before alloHSCT further optimizes outcome, and how the GVL effect after alloHSCT can be optimized. Precision medicine for patients with AML is urgently needed; thus, the decision to perform transplantation or not in an individual patient might depend on weighing the risk of relapse versus the personalized risk of NRM. 
